Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568384 · ClinicalTrials.gov registry record · NA
Evaluation of an Ascensia Blood Glucose Meter and App System
A NA study, sponsored by Ascensia Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT02568384: Completed NA study, sponsored by Ascensia Diabetes Care.
NCT02568384 is a NA study that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02568384, a NA study, has completed, sponsored by Ascensia Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the usability of the Onyx system in the hands of subjects with Insulin Dependent Diabetes Mellitus (IDDM) or insulin-using subjects with Non-IDDM.
Primary Outcome
For "software operations" tasks, subjects rated statements about software operations tasks as 1Strongly Agree, 2Agree, 3Neither Agree nor Disagree, 4Disagree, 5Strongly Disagree, or 6No opinion. Software operations tasks included: * Obtain a synced blood glucose reading * Initiation and use of insulin bolus calculator * Access and interpret glucose displays such as expanded graph (modal day) and sequential views.
Interventions
- DEVICE Onyx BG Meter / App System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-10 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02568384 record still lists
NCT02568384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Onyx BG Meter / App System is the first listed.
NCT02568384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02568384 about?
NCT02568384 is a clinical study titled "Evaluation of an Ascensia Blood Glucose Meter and App System". The purpose of this study is to assess the usability of the Onyx system in the hands of subjects with Insulin Dependent Diabetes Mellitus (IDDM) or insulin-using subjects with Non-IDDM.
What is the current status of trial NCT02568384?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2015-10. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02568384?
The interventions under investigation include: Onyx BG Meter / App System (DEVICE).
Who is sponsoring clinical trial NCT02568384?
This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02568384's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia